Brief: Arch Biopartners Submits Application To Turkey To Conduct Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial For LSALT Peptide
22/09/2023 12:08
Sept 22 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS SUBMITS APPLICATION TO THE TURKISH
MINISTRY OF
HEALTH TO CONDUCT A PHASE II CARDIAC SURGERY ASSOCIATED-ACUTE
KIDNEY INJURY TRIAL FOR LSALT PEPTIDE
* ARCH BIOPARTNERS INC- ON SCHEDULE TO DOSE FIRST PATIENT IN
Q4 OF
2023
* ARCH BIOPARTNERS INC - FOLLOWING APPROVALS FROM MOH AND
ETHICS
COMMITTEE, PATIENT RECRUITMENT IS EXPECTED TO BEGIN AS PLANNED
IN FALL (Q4) OF 2023
Source text for Eikon: ID:nGNXkjPNz
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide